Poorly soluble molecules comprise more than 70% of the small molecule products entering the drug development pipeline today, and are difficult to formulate as tablets. Formulation scientists have found that two-piece, liquid-filled, hard-shell capsules offer several advantages over other solid dosage forms, such as ease of scalability and manufacturing, faster absorption, safer handling of highly potent or complex APIs, and excellent product stability. They can be rapidly developed and tested, moving your product quickly from R&D to clinical trials, reducing overall development time and costs.
